Financial reports
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
25 Feb 22
10-Q
2021 Q3
Quarterly report
5 Nov 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
26 Feb 21
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-Q
2020 Q2
Quarterly report
7 Aug 20
Current reports
8-K
Entry into a Material Definitive Agreement
21 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
18 Nov 22
8-K
Other Events
7 Nov 22
8-K
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
3 Nov 22
8-K
Regulation FD Disclosure
13 Sep 22
8-K
Entry into a Material Definitive Agreement
23 Aug 22
8-K
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
22 Aug 22
8-K
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4 Aug 22
8-K
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
1 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 22
Registration and prospectus
15-12G
Securities registration termination
1 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
25-NSE
Exchange delisting
21 Nov 22
Proxies
DEFA14A
Additional proxy soliciting materials
7 Nov 22
DEFM14A
Proxy related to merger
7 Oct 22
PREM14A
Preliminary proxy related to merger
21 Sep 22
DEFA14A
Additional proxy soliciting materials
23 Aug 22
DEFA14A
Additional proxy soliciting materials
23 Aug 22
DEFA14A
Additional proxy soliciting materials
22 Aug 22
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
Other
UPLOAD
Letter from SEC
18 Nov 21
CORRESP
Correspondence with SEC
10 Nov 21
UPLOAD
Letter from SEC
20 Oct 21
CT ORDER
Confidential treatment order
30 Nov 18
UPLOAD
Letter from SEC
31 Jul 17
CORRESP
Correspondence with SEC
28 Jul 17
UPLOAD
Letter from SEC
19 Jul 17
CT ORDER
Confidential treatment order
23 Jan 15
EFFECT
Notice of effectiveness
10 Nov 14
EFFECT
Notice of effectiveness
24 Oct 13
Ownership